Healthcare provider profile · identity verified

Hashani Malik Perkins, M.D.

Allopathic & Osteopathic Physicians|General Practice · ZEPHYRHILLS, FL · NPI 1700229838

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Hashani Malik Perkins, M.D. received $14.96 in general payments during 2025 across 1 reported records.

Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$14.96

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Exact Sciences Corporation Unresolved — no canonical attribution shown $14.96100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$14.961

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Cologuard Collection Kit
Normalized: cologuard collection kit
Device Exact Sciences Corporation $14.96 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium15186
Amlodipine BesylateAmlodipine Besylate10852
GabapentinGabapentin8740
AzithromycinAzithromycin8571
Levothyroxine SodiumLevothyroxine Sodium8344
Potassium ChloridePotassium Chloride8241
FurosemideFurosemide8039
Pantoprazole SodiumPantoprazole Sodium7943
Losartan PotassiumLosartan Potassium7839
PrednisonePrednisone7348
Albuterol Sulfate HfaAlbuterol Sulfate7130
LisinoprilLisinopril6943
Metoprolol TartrateMetoprolol Tartrate6933
Metformin HclMetformin Hcl6228
AlprazolamAlprazolam5322
Tamsulosin HclTamsulosin Hcl5125
Tramadol HclTramadol Hcl4722
MeloxicamMeloxicam4625
Diclofenac SodiumDiclofenac Sodium4326
OmeprazoleOmeprazole4326
Trazodone HclTrazodone Hcl3926
CefuroximeCefuroxime Axetil3837
Duloxetine HclDuloxetine Hcl3817
CarvedilolCarvedilol3717
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3518
Rosuvastatin CalciumRosuvastatin Calcium3421
Ciprofloxacin HclCiprofloxacin Hcl3329
Montelukast SodiumMontelukast Sodium3314
Sertraline HclSertraline Hcl3317
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide3215
ClopidogrelClopidogrel Bisulfate3115
Metoprolol SuccinateMetoprolol Succinate3118
Cyclobenzaprine HclCyclobenzaprine Hcl2914
Doxycycline MonohydrateDoxycycline Monohydrate2826
GlipizideGlipizide2814
Tizanidine HclTizanidine Hcl2820
EliquisApixaban26suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid26suppressed
Fluticasone PropionateFluticasone Propionate2414
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2414
MounjaroTirzepatide23suppressed
Warfarin SodiumWarfarin Sodium23suppressed
Hydralazine HclHydralazine Hcl22suppressed
Pravastatin SodiumPravastatin Sodium2212
JardianceEmpagliflozin2111
Zolpidem TartrateZolpidem Tartrate20suppressed
LevofloxacinLevofloxacin1915
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19suppressed
CelecoxibCelecoxib18suppressed
EzetimibeEzetimibe18suppressed
FluconazoleFluconazole1814
Oxycodone HclOxycodone Hcl18suppressed
SimvastatinSimvastatin18suppressed
Testosterone CypionateTestosterone Cypionate18suppressed
BaclofenBaclofen1711
FamotidineFamotidine17suppressed
FinasterideFinasteride17suppressed
HydrochlorothiazideHydrochlorothiazide17suppressed
Ondansetron HclOndansetron Hcl17suppressed
SucralfateSucralfate17suppressed
AllopurinolAllopurinol16suppressed
ClonazepamClonazepam16suppressed
OzempicSemaglutide16suppressed
PregabalinPregabalin16suppressed
Alendronate SodiumAlendronate Sodium15suppressed
Donepezil HclDonepezil Hcl15suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15suppressed
MethylprednisoloneMethylprednisolone1515
MetolazoneMetolazone1511
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14suppressed
Enalapril MaleateEnalapril Maleate14suppressed
Ondansetron OdtOndansetron14suppressed
Clonidine HclClonidine Hcl13suppressed
KetoconazoleKetoconazole13suppressed
ValacyclovirValacyclovir Hcl1312
Vitamin D2Ergocalciferol (Vitamin D2)13suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1212
Breo ElliptaFluticasone/Vilanterol12suppressed
Diltiazem HclDiltiazem Hcl12suppressed
Meclizine HclMeclizine Hcl12suppressed
Paroxetine HclParoxetine Hcl12suppressed
Sildenafil CitrateSildenafil Citrate12suppressed
Bupropion XlBupropion Hcl11suppressed
Insulin LisproInsulin Lispro11suppressed
MetronidazoleMetronidazole1111
Ropinirole HclRopinirole Hcl11suppressed
SpironolactoneSpironolactone11suppressed
TemazepamTemazepam11suppressed
TopiramateTopiramate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $14.96 · 1 records Exact Sciences Corporation Cologuard Collection Kit
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error